174900 fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
AbClon, Inc. engages in the development, manufacture and sale of antibody drugs. The firm was established to develop bio-synergy antibody therapeutics for overcoming intractable cancer. It offers antibodies and detection kits. The company was founded by Carl Erik Mathias Uhlén and Jong-Seo Lee on June 25, 2010 and is headquartered in Seoul, South Korea.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
174900 does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company